Behandling av bipolar lidelse under svangerskap og etter fodsel

Tidsskrift for den Norske Laegeforening

Volumn 131, Issue 2, 2011, Pages 126-129

  Berle, Jan Oystein ^a   Solberg, Dag Kristen ^b   Spigset, Olav ^c,d  

^a Psykiatrisk divisjon Kronstad distriktspsykiatriske senter   (Norway)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT; TRANQUILIZER; TRIAZINE DERIVATIVE; VALPROIC ACID;

BIPOLAR DISORDER; DRUG CONTRAINDICATION; DRUG EFFECT; FEMALE; HUMAN; LACTATION; PREGNANCY; PREGNANCY COMPLICATION; PSYCHOLOGICAL ASPECT; PUERPERAL DISORDER; REVIEW; RISK FACTOR;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; LACTATION; LITHIUM COMPOUNDS; PREGNANCY; PREGNANCY COMPLICATIONS; PUERPERAL DISORDERS; RISK FACTORS; TRIAZINES; VALPROIC ACID;

EID: 79551558841     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.09.1411     Document Type: Review

References (31)

1. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry 1987; 150: 662-73.
2. Bratfos O, Haug JO. Puerperal mental disorders in manic-depressive females. Acta Psychiatr Scand 1966; 42: 285-94.
3. Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord 2004; 6: 2-13.
4. Viguera AC, Nonacs R, Cohen LS et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000; 157: 179-84.
5. Viguera AC, Tondo L, Baldessarini RJ. Sex differences in response to lithium treatment. Am J Psychiatry 2000; 157: 1509-11.
6. Hunt N, Silverstone T. Does puerperal illness distinguish a subgroup of bipolar patients? J Affect Disord 1995; 34: 101-7.
7. Nager A, Sundquist K, Ramírez-León V et al. Obstetric complications and postpartum psychosis: a follow-up study of 1.1 million first-time mothers between 1975 and 2003 in Sweden. Acta Psychiatr Scand 2008; 117: 12-9.
8. Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-55.
9. Yonkers KA, Wisner KL, Stowe ZN et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161: 608-20.
10. Dodd S, Berk M. The safety of medications for the treatment of bipolar disorder during pregnancy and the puerperium. Curr Drug Saf 2006; 1: 25-33.
11. Ward S, Wisner KL. Collaborative management of women with bipolar disorder during pregnancy and postpartum: pharmacologic considerations. J Midwifery Womens Health 2007; 52: 3-13.
12. Cohen LS, Nonacs RM, red. Mood and anxiety disorders during pregnancy and postpartum. I: Oldham JM, Riba MB, red. Review of Psychiatry Series. Bd. 24, nr. 4. Washington D.C.: American Psychiatric Publishing, 2005.
13. Freeman MP, Gelenberg AJ. Bipolar disorder in women: reproductive events and treatment considerations. Acta Psychiatr Scand 2005; 112: 88-96.
14. Cohen LS, Friedman JM, Jefferson JW et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146-50.
15. Newport DJ, Viguera AC, Beach AJ et al. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry 2005; 162: 2162-70.
16. Schou M. Forty years of lithium treatment. Arch Gen Psychiatry 1997; 54: 9-15.
17. Gentile S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipolar Disord 2006; 8: 207-20.
18. Nguyen HT, Sharma V, McIntyre RS. Teratogenesis associated with antibipolar agents. Adv Ther 2009; 26: 281-94.
19. Meador KJ, Baker GA, Browning N et al; NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360: 1597-605.
20. Holmes LB, Baldwin EJ, Smith CR et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008; 70: 2152-8.
21. Salgado MD, Morales A, Gomez RS et al. Gestational lamotrigine monotherapy: congenital malformations and psychomotor development. Epilepsia 2004; 45: 229-30.
22. Tomson T, Battino D. Pregnancy and epilepsy: what should we tell our patients? J Neurol 2009; 256: 856-62.
23. McKenna K, Koren G, Tetelbaum M et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005; 66: 444-9.
24. Newham JJ, Thomas SH, MacRitchie K et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 2008; 192: 333-7.
25. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Women Ment Health 2005; 8: 77-87.
26. Berle JØ. Alvorlig depresjon og psykose post partum - når bør elektrokonvulsiv behandling brukes? Tidsskr Nor Lægeforen 1999; 119: 3000-3.
27. Brockington IF. Diagnosis and management of post-partum disorders: a review. World Psychiatry 2004; 3: 89-95.
28. Viguera AC, Newport DJ, Ritchie J et al. Lithium in breast milk and nursing infants: clinical implications. Am J Psychiatry 2007; 164: 342-5.
29. Newport DJ, Pennell PB, Calamaras MR et al. Lamotrigine in breast milk and nursing infants: determination of exposure. Pediatrics 2008; 122: e223-31.
30. Gardiner SJ, Kristensen JH, Begg EJ et al. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants. Am J Psychiatry 2003; 160: 1428-31.
31. Misri S, Corral M, Wardrop AA et al. Quetiapine augmentation in lactation: a series of case reports. J Clin Psychopharmacol 2006; 26: 508-11.